Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful

Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type.

from Reuters: Health News https://ift.tt/2ZT7rvU
via IFTTT